Netskrt to Showcase Media Over QUIC Work with Oracle at IBC 2026
10.9.2026 14:00:00 CEST | Business Wire | Press Release
Netskrt, an independent content delivery network built for high-concurrency streaming events, today announced that it will showcase its work to advance Media Over QUIC (MOQ) at IBC 2026, taking place Sept. 11-14 at RAI Amsterdam. As part of the event, Netskrt will demonstrate with Oracle how independently operated CDN infrastructure can participate in a coordinated MOQ delivery path designed to bring live media closer to viewers.
MOQ is an emerging IETF effort designed to support low-latency media delivery at scale, with live streaming among its primary use cases. Its relay-based architecture enables media to move through distributed infrastructure closer to audiences, creating new possibilities for reducing latency while efficiently serving highly concurrent live events.
At IBC, Netskrt and Oracle will put that model into practice. An Oracle Video Edge (OVE) containerized relay running within Netskrt infrastructure will coordinate with Oracle’s relay network as part of an end-to-end MOQ delivery path. The demonstration illustrates how infrastructure operated by an independent CDN can work within a larger coordinated architecture.
“The advancement of MOQ is imperative because it aligns precisely with where live streaming infrastructure needs to go,” said Siegfried Luft, Co-founder and CEO of Netskrt. “Large live events require enormous capacity, but that capacity is spread across clouds, CDNs, and broadband networks. Giving those independently operated environments a more effective way to work together can help bring content closer to viewers and create a more responsive delivery model for the biggest moments in streaming.”
Netskrt’s work with Oracle reflects the company’s broader approach to content delivery. Netskrt brings streaming infrastructure closer to subscribers and extends capacity into the networks that ultimately serve them, an architecture particularly suited to the sharp demand peaks created by live sports and other high-concurrency events.
MOQ adds a common transport and relay model that can enable independently operated infrastructure to participate in a coordinated delivery path. For live streaming platforms, that approach has the potential to provide shorter paths between content and viewers, access to distributed capacity where demand is highest, and greater flexibility as network conditions change.
“The promise of MOQ depends on making interoperability work across the infrastructure that already powers the media ecosystem,” said Gaurab Upadhaya, Core Infrastructure Engineering Architect, Media Services at Oracle. “Our work with Netskrt demonstrates how relay capacity operating within an independent CDN can coordinate with Oracle Video Edge as part of a common delivery path. That type of collaboration is an important step toward making low-latency live delivery practical at scale.”
On Sept. 12, Netskrt will join Oracle and Paramount for “Beyond Broadcast: MOQ for Live Delivery” in the IBC Showcase Theatre. The session will demonstrate a working end-to-end pipeline in which Paramount content flows through Oracle Video Edge, reaches a Netskrt endpoint, and plays in the Paramount player. The companies will also discuss how they connected the different components, the architectural decisions behind the implementation, and lessons from building the system.
MOQ remains an emerging standard, with continued work underway around specifications, interoperability, deployment models, and commercial adoption. For Netskrt, IBC represents an opportunity to show that the industry is moving beyond architectural concepts and beginning to demonstrate how coordinated MOQ infrastructure can function across organizational boundaries.
“The next generation of live streaming will require networks that can cooperate as effectively as they scale,” added Luft. “IBC gives us an opportunity to show what that looks like in real infrastructure and to work alongside Oracle and Paramount on the technologies that can make real-time streaming better for viewers.”
About Netskrt Systems
Netskrt is disrupting the CDN space by improving economics up and down the streaming value chain while focusing on use cases that deliver large and complex content downloads. Live tier-one sports, hotly anticipated game drops, and video-on-demand are delivered more efficiently and with higher quality of experience. The Netskrt CDN accomplishes this through dynamically instantiated capacity, global reach, and last-mile awareness.
About Oracle Cloud Infrastructure
Oracle Cloud Infrastructure (OCI) offers secure, high-performance cloud infrastructure services designed to help organizations run a wide range of enterprise and media workloads with flexibility and scale. OCI supports multicloud and distributed cloud strategies while helping customers optimize performance, resiliency, and operational efficiency. For more information about Oracle (NYSE: ORCL), please visit us at www.oracle.com. Oracle is a registered trademark of Oracle Corporation.
For more information, visit www.netskrt.io.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260910394672/en/
Contacts
Lucy Nguyen
lucy@magnoliamc.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press Release
Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom